<?xml version="1.0" encoding="UTF-8"?>
<p>Thirty clinical MRSA isolates were collected from King Abdulaziz Specialist Hospital, Taif, Saudi Arabia. The isolates were identified as 
 <italic>S. aureus</italic>, as described previously [
 <xref rid="B49-pharmaceuticals-13-00369" ref-type="bibr">49</xref>]. The methicillin resistance phenotype was performed by the Vitek 2 system (bioMÃ©rieux, Durham, North CA, USA) in accordance with the British Society for Antimicrobial Chemotherapy (BSAC). Each isolate was considered as methicillin-resistant when the minimum inhibitory concentration (MIC) breakpoint of oxacillin was &gt;2 mg/L and cefoxitin &gt;4 mg/L. [
 <xref rid="B50-pharmaceuticals-13-00369" ref-type="bibr">50</xref>]. 
 <italic>S. aureus</italic> ATCC 25922 was used as control.
</p>
